What is the maximum recommended dose of trospium for adults (including immediate‑release and extended‑release formulations)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Maximum Dose of Trospium

The maximum recommended dose of trospium is 60 mg once daily for the extended-release formulation or 20 mg twice daily (total 40 mg/day) for the immediate-release formulation 1.

Formulation-Specific Dosing

Extended-Release (ER) Formulation

  • Standard dose: 60 mg once daily in the morning
  • Must be taken on an empty stomach with water, at least one hour before a meal 1
  • This represents the maximum approved dose for the ER formulation

Immediate-Release (IR) Formulation

  • Standard dose: 20 mg twice daily (total 40 mg/day)
  • While research has evaluated higher doses up to 360 mg in single-dose safety studies 2, these are not clinically recommended
  • The therapeutic daily dose remains up to 40 mg total 2

Important Dosing Considerations

Renal impairment: Trospium ER is not recommended for patients with severe renal impairment (creatinine clearance <30 mL/minute) 1. The drug is primarily excreted unchanged in urine, making dose adjustments critical in renal dysfunction.

Food effects: Administration with high-fat meals reduces bioavailability by 35% for AUC and 60% for peak concentration 1. This is why the ER formulation must be taken on an empty stomach.

Clinical Context

The 60 mg ER formulation was specifically designed to provide once-daily dosing convenience while maintaining efficacy comparable to the 20 mg twice-daily IR formulation, but with lower peak plasma concentrations (2 ng/mL vs 2.7 ng/mL) 3. This pharmacokinetic profile may reduce the likelihood of adverse events while maintaining therapeutic benefit 4, 5, 6.

The most common adverse effects at therapeutic doses include dry mouth (8.7-12.9%) and constipation (7.5-9.4%), with notably low rates of CNS effects 4, 6, 7.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.